About
Maria Fardis joined Frazier Life Sciences as a Venture Partner in 2021 and has more than 20 years of scientific and management experience across public and private companies. She currently serves as CEO of Lassen Therapeutics and previously held leadership roles including President and CEO of Iovance Biotherapeutics, COO of Acerta Pharma, and senior positions at Pharmacyclics and Gilead Sciences. She holds a Ph.D. in Organic Chemistry from UC Berkeley, a B.S. in chemistry from the University of Illinois, Urbana-Champaign, and an M.B.A. from Golden Gate University.
Invests in
Biotech
Experience
- AirNexis Therapeutics Inc.Chief Executive Officercurrent2026 β present
- CRISPR TherapeuticsMember Board Of Directorscurrent2022 β presentCambridge, Massachusetts, United States
- Obsidian TherapeuticsChair Of The Board Of Directorscurrent2021 β presentCambridge, Massachusetts, United States
- Frazier Healthcare PartnersVenture Partnercurrent2021 β presentSan Francisco Bay Area
- Quanta TherapeuticsMember Board of Directorscurrent2021 β presentSouth San Francisco, California, United States
- Lassen TherapeuticsChief Executive Officer2023 β 2026San Diego, California, United States
- Kartos TherapeuticsMember Board Of Directors2018 β 2021Redwood Shores
- Iovance Biotherapeutics, Inc.President & Chief Executive Officer2016 β 2021San Francisco Bay Area
- Acerta Pharma B.V.Chief Operating Officer2015 β 2016San Carlos, CA
- PharmacyclicsChief of Oncology Operations and Alliances2013 β 2014Sunnyvale, CA
- PharmacyclicsEVP of Operations and Alliances2012 β 2013
- PharmacyclicsVP, Alliances and Global Project Management2011 β 2012Sunnyvale, CA
- PharmacyclicsSenior Director, Global Project Management2011Sunnyvale, CA
- Gilead SciencesAssociate Director, Project and Portfolio Management2010 β 2011
- Gilead SciencesSenior Manager, Project and Portfolio Management2006 β 2010
- Gilead SciencesSenior Scientist, Medicinal Chemistry2005 β 2006
- Gilead SciencesScientist II, Medicinal Chemistry2004 β 2005
- Gilead SciencesScientist, Medicinal Chemistry2001 β 2004
- Intrabiotics PharmaceuticalsScientist, Medicinal Chemistry2001
- Kosan Biosciences acquired by Brisol-Myers SquibbScientist, Medicinal Chemistry1998 β 2000
Education
- Golden Gate UniversityMBA, Management2004 β 2007
- University of California, BerkeleyPh.D., Organic Chemistry1993 β 1998
- University of Illinois Urbana-ChampaignB.S., Organic Chemistry1989 β 1992
Skills & more
+12 more
Regulatory AffairsDrug DevelopmentCross-functional Team LeadershipBiopharmaceuticalsFDAFormulationInfectious DiseasesRegulatory SubmissionsCTMSINDPharmaceutical IndustryCROFrom Maria's professional profile.
Same school
Also attended Golden Gate University27
+ 21 more
Also attended University of California, Berkeley863
+ 857 more
Also attended University of Illinois Urbana-Champaign259
+ 253 more
Shared employers
Also worked at Kartos Therapeutics2
Also worked at Iovance Biotherapeutics, Inc.1
Also worked at Gilead Sciences20
+ 14 more
Also worked at Kosan Biosciences acquired by Brisol-Myers Squibb1
Deals Β· 1
Quanta Therapeutics, Inc.Board seat
via Frazier Life Sciences Β· filed Jun 2026 Β· $89.1M raise
Attribution from SEC filings, press coverage, and firm rosters.






.jpeg)







%20(1).png)







.png)









